Dr. Theresa M. Medina
Claim this profileUniversity of Colorado Hospital
Expert in Skin Cancer
Studies Melanoma
20 reported clinical trials
32 drugs studied
About Theresa M. Medina
Education:
- Obtained MD from the University of Colorado School of Medicine in 2015.
- Completed Residency in Internal Medicine at the University of Colorado Hospital in 2018.
- Finished Fellowship in Hematology/Oncology at the University of Colorado Hospital in 2021.
Experience:
- Currently serves as a Hematology and Oncology specialist at the University of Colorado Hospital.
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
BRAF positive
2Melanoma
Stage IV
Stage III
BRAF positive
Affiliated Hospitals
Clinical Trials Theresa M. Medina is currently running
Tuvusertib + Avelumab
for Merkel Cell Skin Cancer
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor cell replication and survival. It may lead to tumor cell death by inhibiting ATR kinase activity. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tuvusertib in combination with avelumab may lengthen the time before Merkel cell cancer starts getting worse compared to giving avelumab alone.
Recruiting1 award Phase 210 criteria
RP1
for Advanced Skin Cancer in Transplant Patients
This trial tests RP1, a modified virus, in organ transplant recipients with advanced skin cancer. RP1 works by killing cancer cells and boosting the immune system to fight the cancer. The HIV-1 accessory protein Vpr has been shown to induce cell cycle arrest and kill tumor cells by apoptosis.
Recruiting1 award Phase 1 & 210 criteria
More about Theresa M. Medina
Clinical Trial Related5 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Theresa M. Medina has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Avelumab
- TSR-022
- Relatlimab
Breakdown of trials Theresa M. Medina has run
Skin Cancer
Melanoma
Cancer
Merkel Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Theresa M. Medina specialize in?
Theresa M. Medina focuses on Skin Cancer and Melanoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Theresa M. Medina currently recruiting for clinical trials?
Yes, Theresa M. Medina is currently recruiting for 5 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Theresa M. Medina has studied deeply?
Yes, Theresa M. Medina has studied treatments such as Nivolumab, Pembrolizumab, Ipilimumab.
What is the best way to schedule an appointment with Theresa M. Medina?
Apply for one of the trials that Theresa M. Medina is conducting.
What is the office address of Theresa M. Medina?
The office of Theresa M. Medina is located at: University of Colorado Hospital, Aurora, Colorado 80045 United States. This is the address for their practice at the University of Colorado Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.